Medigen Vaccine Biologics Statistics

Total Valuation

Medigen Vaccine Biologics has a market cap or net worth of TWD 12.59 billion. The enterprise value is 11.12 billion.

Market Cap	12.59B
Enterprise Value	11.12B

Important Dates

The last earnings date was Friday, November 1, 2024.

Earnings Date	Nov 1, 2024
Ex-Dividend Date	n/a

Share Statistics

Medigen Vaccine Biologics has 328.73 million shares outstanding. The number of shares has decreased by -0.81% in one year.

Current Share Class	n/a
Shares Outstanding	328.73M
Shares Change (YoY)	-0.81%
Shares Change (QoQ)	-4.08%
Owned by Insiders (%)	0.29%
Owned by Institutions (%)	3.24%
Float	250.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	19.22
PB Ratio	3.13
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-17.36
EV / Sales	17.16
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-84.31

Financial Position

The company has a current ratio of 12.69, with a Debt / Equity ratio of 0.08.

Current Ratio	12.69
Quick Ratio	10.16
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	-2.21
Interest Coverage	-24.69

Financial Efficiency

Return on equity (ROE) is -15.48% and return on invested capital (ROIC) is -7.67%.

Return on Equity (ROE)	-15.48%
Return on Assets (ROA)	-7.39%
Return on Capital (ROIC)	-7.67%
Revenue Per Employee	6.29M
Profits Per Employee	-6.22M
Employee Count	103
Asset Turnover	0.12
Inventory Turnover	0.32

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -43.51% in the last 52 weeks. The beta is 0.71, so Medigen Vaccine Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.71
52-Week Price Change	-43.51%
50-Day Moving Average	42.67
200-Day Moving Average	50.09
Relative Strength Index (RSI)	37.70
Average Volume (20 Days)	735,059

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Medigen Vaccine Biologics had revenue of TWD 648.17 million and -640.49 million in losses. Loss per share was -1.97.

Revenue	648.17M
Gross Profit	443.50M
Operating Income	-646.54M
Pretax Income	-640.49M
Net Income	-640.49M
EBITDA	-515.42M
EBIT	-646.54M
Loss Per Share	-1.97

Full Income Statement

Balance Sheet

The company has 1.76 billion in cash and 291.57 million in debt, giving a net cash position of 1.47 billion or 4.47 per share.

Cash & Cash Equivalents	1.76B
Total Debt	291.57M
Net Cash	1.47B
Net Cash Per Share	4.47
Equity (Book Value)	3.86B
Book Value Per Share	12.24
Working Capital	2.34B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -92.44 million and capital expenditures -39.47 million, giving a free cash flow of -131.91 million.

Operating Cash Flow	-92.44M
Capital Expenditures	-39.47M
Free Cash Flow	-131.91M
FCF Per Share	-0.40

Full Cash Flow Statement

Margins

Gross margin is 68.42%, with operating and profit margins of -99.75% and -98.81%.

Gross Margin	68.42%
Operating Margin	-99.75%
Pretax Margin	-98.81%
Profit Margin	-98.81%
EBITDA Margin	-79.52%
EBIT Margin	-99.75%
FCF Margin	-20.35%

Dividends & Yields

Medigen Vaccine Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.81%
Shareholder Yield	0.81%
Earnings Yield	-5.15%
FCF Yield	-1.05%

Stock Splits

The last stock split was on August 3, 2022. It was a forward split with a ratio of 1.48280574.

Last Split Date	Aug 3, 2022
Split Type	Forward
Split Ratio	1.48280574

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a